TITLE

CLINICAL STUDIES OF NORPACE (Part III)

AUTHOR(S)
Kalmansohn, Robert G.
PUB. DATE
January 1975
SOURCE
Angiology;Jan1975 Part 2, Vol. 26, p137
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Examines the effectiveness of Norpace therapy among patients who had been on antiarrhythmic agents. Indications of toxicity in anticholinergic effects; Medical history of the patients; Use of oral Norpace in controlling ventricular tachycardia.
ACCESSION #
16358722

 

Related Articles

  • PAPAVERINE AS AN ANTIARRHYTHMIC AGENT. Whipple, Gerald H. // Angiology;Nov1977, Vol. 28 Issue 11, p737 

    Suggests a chain of events, originating in the clinical experience with papaverine as a vasodilating agent, which may explain the relative lack of attention paid to papaverine as an antiarrhythmic agent. Speculations and suggestions about how papaverine might best be used in antiarrhythmia...

  • CONTROL OF INTRACTABLE ARRHYTHMIAS BY THE USE OF PROPRANOLOL AND CARDIAC PACING -- REPORT OF TWO CASES. leon-Sotomayor, Luis // Angiology;Dec1974, Vol. 25 Issue 11, p729 

    These two cases probably represent some variant of the sick sinus syndrome. In this entity the inappropriate functioning of the sinus node lead to slow and rapid dysrhythmia, although other possible factors may have also contributed to the arrhythmias. The use of the transvenous ventricular...

  • Effects of Antiarrhythmic Agents on Cardiac Function. Gottdiener, John S.; DiBianco, Robert; Fletcher, Ross D. // Angiology;Apr1982, Vol. 33 Issue 4, p228 

    Studies the effects of antiarrhythmic agents on cardiac function. Membrane depressant agents; Cardiac effects of antiarrhythmic agents; Beta-blocking agents.

  • A New Drug for Rapid Conversion of Atrial Fibrillation. DiMarco, John P. // Clinical Cardiology Alert;May2008, Vol. 27 Issue 5, p37 

    VERNAKALANT IS A NEW INVESTIGATIONAL ANTI-arrhythmic drug. The compound is relatively selective, blocking the early-activating potassium channel and the frequency-dependent sodium channel. Vernakalant has a half-life of two to three hours. This study evaluates the ability of intravenous...

  • Selected cardiovascular agents.  // Formulary;Jan2005, Vol. 40 Issue 1, p32 

    Presents information on selected cardiovascular agents available in the United States. Azimilide; Dronedarone; Tecadenoson; Tedisamil; Enoximone; Oxypurinol; Tolvaptan.

  • FDA actions.  // Neurology Alert;Feb2012 Pharmacology, p2 

    The article reports on drug approvals made by the U.S. Food and Drug Administration (FDA) for the manufacture of generic a storvastatin (Lipitor) by Ranbaxy Laboratories and Prevnar 13 vaccine for adults by Wyeth Pharmaceuticals and the restriction in prescriptions of Dronedarone (Multaq), an...

  • flecainide.  // Davis's Drug Guide for Nurses, 10th edition;2007, p523 

    This article presents a nursing guide to the antiarrhythmic agent flecainide. Drug information provided includes pharmacokinetics, contraindications or precautions, adverse reactions or side effects, interactions, route or dosage, and availability. Tambocor is a popular brand of the drug....

  • Review rules out rosuvastatin use.  // Pulse;5/3/2007, Vol. 67 Issue 17, p6 

    The article reports that fluvastatin and rosuvastatin should not be used in patients' routine management in Great Britain. Research shows that simvastatin was similarly effective at lower cost. This suggests that many patients who are taking atorvastatin could be changed to simvastatin. Some...

  • Literature Review: CORONARY ARTERY DISEASE--DRUG USE.  // Current Medical Literature: Interventional Cardiology Monitor;2004, Vol. 11 Issue 2, p52 

    Presents the abstracts of research papers on drugs for coronary artery disease published in various journals.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics